Application of the revised International Prognostic Scoring System for myelodysplastic syndromes in Argentinean patients

• Autores: Belli, Carolina Bárbara; Bestach, Yesica Soledad; Giunta, Mario; Iastrebner, Marcelo; Santos, Isabel; Pintos, Noemi; Arbelbide, Jorge; Basquiera, Ana L.; Bengió, Raquel; Larripa, Irene Beatriz
• Año de publicación: 2014
• Idioma: inglés
• Tipo de recurso: artículo
• Materia: Myelodysplastic Syndromes; Ipss-R; Risk; Prognostic
• Institución: Consejo Nacional de Investigaciones Científicas y Técnicas

The International Prognostic Scoring System (IPSS) [1], the gold standard for risk assessment in Myelodysplastic syndromes (MDS), has been recently revised (IPSS-R). The authors proposed a new prognostic model including novel components: five cytogenetic prognostic subgroups with specific classification of a number of less common cytogenetic subsets [2-3]; the <5% bone marrow blasts category was split between 0-2% and >2-<5%; depth of cytopenias at clinically relevant cut-points for haemoglobin level, platelet count and absolute neutrophil count [2]. As the score [2] was established in MDS patients including all French-American-British classification subtypes [4], the aim of this study was to apply the IPSS-R in Argentinean MDS patients classified according to the World Health Organization (WHO) classification [5]. We retrospectively analysed a cohort of 371 de novo MDS patients [6] diagnosed between 1981 and 2012. According to the WHO classification, 43 patients were classified as refractory cytopenia with unilineage dysplasia/ refractory anaemia with ringed sideroblasts, 17 as del(5q) syndrome, 201 as refractory cytopenia with multilineage dysplasia, 44 as RAEB type 1, and 66 as RAEB type 2. The median age was 70 (17-92) years with 72% of patients above 60, the gender ratio was 1.4 (M/F: 214/157), and 157 (42%) patients showed an abnormal karyotype. During the follow-up (median 23.3 months), 80 (22%) showed leukemic progression and 161 (43%) died (median overall survival: 55.5 months). Studied variables (gender and WHO classification, % bone marrow blast, cytogenetic risk category, and depth of cytopenias according to the IPSS-R [2]), and the IPSS [1], IPSS-R (Fig. 1a-b), and IPSS-R adjusted by age (Fig. 1c) [2] systems showed statistical differences for predicting both overall survival and leukemic evolution (see supplementary information). Patients were classified by the IPSS-R as very-low (23%), low (40%), intermediate (15%), high (14%), and very-high risk (9%), with median survival of 125, 62, 44, 19 and 15 months (Fig. 1a), and time to leukemic evolution (25%) of >150, 131, 51, 6, and 5 months, respectively (Fig. 1b). The proposed IPSS-R defines a new intermediate risk group mainly composed by patients from the intermediate-1 IPSS risk category (84%, 47/56) and allowed us to identify 7% (11/150) of patients that were shifted from the intermediate-1 risk group into the high IPSS-R risk group. Although limit age of 60 years did not show statistical differences for predicting survival, our results confirm that younger good risk patients have significantly better prognosis than elderly counterparts (very low/ low risk patients: 125 vs. 64 months, p=0.014), while the age at diagnosis has no impact on disease outcome for higher risk patients [1-2, 7-8]. The proposed formula for an age-adjusted categorization [2] helped us to identify 19% (28/147) of short surviving patients among low risk IPSS-R patients with a median survival of 34 months (Fig. 1d). These patients showed, among relevant parameters, a gender ratio M/F of 3.0, a median age of 81 years, 2.5% of BM blasts, 9.1g/dL of haemoglobin level, 12 (43%) presented an abnormal karyotype and 17 died, including 6 patients with previous leukemic progression. It can be concluded that the IPSS-R system is simple to use since includes accessible variables showing a good reproducibility, effectiveness in predicting clinical outcome, and a refinement of the intermediate risk category in our WHO classified series.
Fil: Belli, Carolina Bárbara. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Bestach, Yesica Soledad. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina
Fil: Giunta, Mario. Instituto Privado de Hematología y Hemoterapia. Paraná; Argentina
Fil: Iastrebner, Marcelo. Centro Médico “San Luis”. Buenos Aires; Argentina
Fil: Santos, Isabel. Ministerio de Defensa. Ejército Argentino. Hospital Militar Central Cirujano Mayor "Dr. Cosme Argerich"; Argentina
Fil: Pintos, Noemi. Sanatorio “Julio Méndez”. Servicio de Hematología. Buenos Aires; Argentina
Fil: Arbelbide, Jorge. Hospital Italiano; Argentina
Fil: Basquiera, Ana L.. Hospital Privado de Córdoba. Córdoba; Argentina
Fil: Bengió, Raquel. Instituto de Investigaciones Hematológicas. Buenos Aires; Argentina
Fil: Larripa, Irene Beatriz. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina. Instituto de Investigaciones Hematológicas. Buenos Aires; Argentina